AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage ...

AstraZeneca CEO Pascal Soriot joins Morning Brief to discuss the outlook for the company and outlines AstraZeneca's plans to ...

Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the ...

CEO Soriot said Europe must boost investment in pharma innovation or risk falling further behind the US in drug development.

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

LONDON (Reuters) -The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance ...

Sir Pascal Soriot is usually several steps ahead of the game, so always worth listening to. His latest red flag is that Europe is falling behind in healthcare innovation and manufacturing ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

Sir Pascal Soriot, AstraZeneca’s chief executive, said governments could “decide to not spend” on new medicines, but “then the jobs and the investments will go elsewhere”. He said ...